Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Biodesix, Inc. (BDSX)

1.35   -0.04 (-2.88%) 06-26 19:19
Open: 1.4 Pre. Close: 1.39
High: 1.42 Low: 1.34
Volume: 1,282,853 Market Cap: 54(M)
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.42 - 1.43 1.43 - 1.44
Low: 1.32 - 1.33 1.33 - 1.34
Close: 1.34 - 1.35 1.35 - 1.36

Technical analysis

as of: 2022-06-24 4:38:20 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.13     One year: 2.54
Support: Support1: 1.25    Support2: 1.03
Resistance: Resistance1: 1.82    Resistance2: 2.18
Pivot: 1.61
Moving Average: MA(5): 1.37     MA(20): 1.57
MA(100): 2     MA(250): 5.27
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 6.8     %D(3): 6.8
RSI: RSI(14): 40.8
52-week: High: 12.98  Low: 1.25
Average Vol(K): 3-Month: 643 (K)  10-Days: 251 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BDSX ] has closed above bottom band by 22.8%. Bollinger Bands are 11.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 16 Jun 2022
Having purchased US$21m worth of Biodesix, Inc. (NASDAQ:BDSX) stock, the recent 18% pullback is not what insiders may have expected - Simply Wall St

Thu, 09 Jun 2022
Biodesix, Inc. (NASDAQ:BDSX) Given Average Rating of “Buy” by Analysts - Defense World

Tue, 07 Jun 2022
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test - Business Wire

Tue, 07 Jun 2022
Should Diagnostics & Research Stock Biodesix Inc (BDSX) Be in Your Portfolio Tuesday? - InvestorsObserver

Tue, 31 May 2022
Do Traders Think Biodesix Inc (BDSX) Can Keep Climbing Tuesday? - InvestorsObserver

Thu, 26 May 2022
Biodesix Stock: Bad Diagnosis (NASDAQ:BDSX) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 27 (M)
Shares Float 10 (M)
% Held by Insiders 68.6 (%)
% Held by Institutions 9.7 (%)
Shares Short 1,310 (K)
Shares Short P.Month 1,060 (K)

Stock Financials

EPS -1.37
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.58
Profit Margin (%) -79.2
Operating Margin (%) -72.2
Return on Assets (ttm) -25
Return on Equity (ttm) -141.8
Qtrly Rev. Growth -73.4
Gross Profit (p.s.) 0.88
Sales Per Share 2.01
EBITDA (p.s.) -1.34
Qtrly Earnings Growth 0
Operating Cash Flow -28 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.99
PEG Ratio 0
Price to Book value 2.28
Price to Sales 0.66
Price to Cash Flow -1.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.